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Abstract
Genetic epidemiologists have taken the challenge to identify genetic polymorphisms involved in the
development of diseases. Many have collected data on large numbers of genetic markers but are
not familiar with available methods to assess their association with complex diseases. Statistical
methods have been developed for analyzing the relation between large numbers of genetic and
environmental predictors to disease or disease-related variables in genetic association studies.
In this commentary we discuss logistic regression analysis, neural networks, including the
parameter decreasing method (PDM) and genetic programming optimized neural networks
(GPNN) and several non-parametric methods, which include the set association approach,
combinatorial partitioning method (CPM), restricted partitioning method (RPM), multifactor
dimensionality reduction (MDR) method and the random forests approach. The relative strengths
and weaknesses of these methods are highlighted.
Logistic regression and neural networks can handle only a limited number of predictor variables,
depending on the number of observations in the dataset. Therefore, they are less useful than the
non-parametric methods to approach association studies with large numbers of predictor variables.
GPNN on the other hand may be a useful approach to select and model important predictors, but
its performance to select the important effects in the presence of large numbers of predictors
needs to be examined. Both the set association approach and random forests approach are able to
handle a large number of predictors and are useful in reducing these predictors to a subset of
predictors with an important contribution to disease. The combinatorial methods give more insight
in combination patterns for sets of genetic and/or environmental predictor variables that may be
related to the outcome variable. As the non-parametric methods have different strengths and
weaknesses we conclude that to approach genetic association studies using the case-control design,
the application of a combination of several methods, including the set association approach, MDR
and the random forests approach, will likely be a useful strategy to find the important genes and
interaction patterns involved in complex diseases.
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The field of genetic epidemiology aims to identify genetic
polymorphisms involved in the development of diseases.
Single-locus methods measure the effect of one locus irre-
spective of other loci and are useful to study genetic dis-
eases caused by a single gene, or even loci within single
genes. To study complex diseases such as cardiovascular
disorders or diabetes single-locus methods may not be
appropriate, as it is possible that loci contribute to a cer-
tain complex disease only by their interaction with other
genes (epistasis), while main effects of the individual loci
may be small or absent [1]. Single-locus methods can not
detect complex patterns [2], thus underestimate the
genetic contribution to disease in the presence of interac-
tions between loci. Therefore, approaches have been
developed that take into account that complex diseases
can be caused by an intricate pattern of genetic variants.
These approaches are referred to as multi-locus methods
and are specifically designed to find multiple disease loci,
possibly on different chromosomes [3]. Diseases with a
polygenic background can be studied by multi-locus
methods, but also multi-factorial diseases by incorporat-
ing environmental predictors into the model.
Studying the effect of multiple genetic and/or environ-
mental predictors and their interactions is fraught with
statistical problems. One of these problems involves mul-
tiple testing. For each tested locus the probability to make
a type I error is present, which is the probability to accept
the hypothesis that the locus has an effect while in reality
it does not. By testing multiple markers independently the
type I error probability of finding a false positive result is
increased. Two correction procedures for multiple testing
are Bonferroni procedure and the false discovery rate [4].
Adjusting for multiple testing leads to a decrease of power
(the probability to detect an effect when the effect is
present) which makes it less likely to find weak genetic
effects. Several multi-locus methods, discussed later in
this commentary, have been developed to solve the mul-
tiple testing problem. These methods have greater power
to detect susceptibility loci than single-marker tests.
The problem of modest sample sizes to test interactions
for a large group of predictors (high-dimensional data) is
referred to as the 'curse of dimensionality' problem [5].
The number of observations becomes too small relative to
the number of predictors tested as few or no observations
for combinations of predictors will occur. Traditional par-
ametric approaches suffer from the dimensionality prob-
lem as it results in inaccurate parameter estimates for
interaction effects [6]. Multi-locus methods are needed to
select from the large amount of genetic and environmen-
tal predictors a small group of predictors and/or interac-
tions between predictors that have a significant effect on
the disease outcome. Subsequently, parameters for the
selected predictors can be estimated by logistic regression
analysis.
A third problem in the analysis of the effect of multiple
genetic and environmental predictors on disease is the
presence of correlated predictors in the dataset. An exam-
ple is the presence of SNPs that are in linkage disequilib-
rium (LD) among the set of SNPs tested for association
with disease. The power of a method to detect important
predictors can be decreased when correlated predictors are
tested. Some of the multi-locus methods discussed in this
commentary are able to handle correlated predictors. Very
high correlations between predictors, which is referred to
as multicollinearity, is always a problem for methods:
highly correlated predictors have an equal chance to be
selected and one predictor may falsely be selected instead
of the highly correlated predictor that is truly associated
with disease. Multicollinearity can be coped with statisti-
cally by combining data from multiple predictors into a
single variable [7], for example combining SNPs that are
in high LD into haplotypes.
Another difficult problem is the presence of heterogeneity
[8]. Genetic heterogeneity is present if different genetic
loci are independently associated with the same disease.
The genes in which these loci are present can be part of
different etiological pathways leading to the same disease
or be part of the same pathway. Irrespective of the biolog-
ical mechanism that gives rise to genetic heterogeneity,
the association of these loci with the disease will be
reduced if the total sample is used for measuring the asso-
ciation. A method that is not robust in the presence of
genetic heterogeneity will likely suffer from a decrease in
power to detect genetic effects. If genetic heterogeneity is
not handled it can be accounted for by employing cluster
analysis of genetic markers to identify groups of individu-
als with similar genetic profiles [8]. If clusters are present,
association analyses of markers with the outcome variable
should be accommodated for cluster effects [9]. Another
form of heterogeneity that can affect the power to detect
markers associated with disease is the presence of pheno-
copies. Phenocopies are individuals affected by the dis-
ease while they have a low-risk genotype profile. These
individuals have developed the disease due to certain
environmental factors. As in the presence of genetic heter-
ogeneity, phenocopies will decrease the association
between genetic markers and the disease if the association
is studied using the total sample. Cluster analysis of envi-
ronmental factors in the population can be used to define
subgroups and cluster effects should be taken into
account in the association analyses.
Many genetic epidemiologists have collected data on large
numbers of genetic markers but are not familiar with the
available methods to assess their association with com-Page 2 of 15
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weaknesses of methods for analyzing the genetic and/or
environmental effects on disease or disease-related varia-
bles. These methods are presented in figure 1. Logistic
regression and neural networks are discussed so as to com-
pare non-parametric methods with these more 'tradi-
tional' statistical methods. The non-parametric methods
have been selected as several genetic association studies
have been conducted using these methods to analyze their
data. This field is rapidly in progress and more methods
are becoming available. This commentary does not pre-
tend to cover all available multi-locus methods, nor to
provide their statistical background, but aims to function
as a starting and reference point for researchers in the field
of genetic epidemiology who want to become more
acquainted with multi-locus methods.
Method of evaluation
To provide an overview of the strengths and weaknesses of
each method the ability of the methods to model the
effects of multiple genetic and/or environmental predic-
tors on disease outcome is evaluated for the following fea-
tures:
- are the methods able to handle large numbers of predic-
tors relative to the number of observations (dimensional-
ity problem);
- number of predictors that can be analyzed in modest
sample sizes;
- power to detect genetic effects;
- how do the methods handle interactions;
- do the methods maintain power if correlated predictors
are present in the dataset;
- performance of the method if genetic heterogeneity is
present;
- software availability and whether available software is
open-source.
For each method a description is given followed by the
discussion of the performance of the method for the dif-
ferent features. First, logistic regression is discussed, fol-
lowed by neural networks, the set association approach,
the combinatorial methods and the random forests
Diagram containing the different methods described in this commentaryFigure 1
Diagram containing the different methods described in this commentary.
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strengths and weaknesses of these methods are compared
and a strategy to analyze the effect of multiple genetic and
environmental predictors on disease is proposed. As
many of these methods use permutation testing to deter-
mine the statistical significance of predictors a short expla-
nation of this test will be given here.
For testing the statistical significance of the association
between selected predictors and the outcome variable per-
mutation tests are used to obtain the distribution of the
test statistic under the null hypothesis of no association.
Permutation tests generate many samples for which the
association between the predictors and the outcome vari-
able has been disrupted by randomly distributing the val-
ues of the predictors or outcome variable over the
observations. For each permuted sample the method is
applied to calculate the test statistic and together these test
statistics form the distribution of the test statistic under
the null hypothesis. The proportion of permutation sam-
ples with a value exceeding the value of the test statistic of
the observed data gives the significance level for the
observed test statistic [10].
To evaluate the ability of a model to classify and predict a
certain outcome variable, multi-fold cross-validation is
often used. This procedure will be explained because dif-
ferent methods use multi-fold cross-validation to obtain
the classification and prediction error of models relating
predictors to a certain outcome variable. In multi-fold
cross-validation the data are randomly divided into
groups of approximately the same size. The parameters of
the model are estimated by all groups except for one, this
remaining group is used for obtaining the prediction error
(or prediction accuracy) of the model. As an example, a
ten-fold cross-validation divides the data into ten groups
of equal size. Nine groups are used to build the model. For
quantitative traits, a fraction of the prediction error of this
model is computed by the remaining group. By turns the
ten groups are used to compute a fraction of the predic-
tion error and the sum of the ten fractions forms the pre-
diction error. For categorical outcome variables (e.g.
disease status) the prediction error is calculated for each of
the ten groups.
To reduce arbitrariness in the division of the data into the
different groups when estimating the expected (average)
prediction error, the multi-fold cross-validation is
repeated several times. Each time the data is randomly
divided into the same number of groups. For quantitative
traits the sum of the prediction errors obtained by the dif-
ferent cross-validations divided by the number of repeats
gives an average prediction error. For dichotomic traits the
average prediction error is the sum of prediction errors
over all groups divided by the number of groups. The aver-
age prediction error is an unbiased estimate of the predic-
tion error of the model.
Traditional methods
Logistic regression
A parametric statistical method often applied in genetic
epidemiology is logistic regression. It is used to analyze
the effect of genetic and environmental predictors on a
dichotomic outcome, for example disease status. Predic-
tors are linked to the outcome variable by the logit func-
tion. While many methods can be used to test for an
association between predictors and disease in case-control
studies, in such case-control studies logistic regression is
the only appropriate method to consistently estimate the
strength of association between a predictor and disease
[11]. The conditional logistic regression (CLR) method is
appropriate if stratification is present in the data, for
example in a study design with matched cases and con-
trols. CLR adjusts for the matching of the cases and con-
trols by stratifying the matched case-control pairs.
Features of the logistic regression method
One of the disadvantages of the logistic regression
method is that it performs poorly in the presence of the
dimensionality problem; it may lead to false positive
results [12] and a low power to detect interactions [6].
This may be overcome by stepwise regression analysis,
which reduces the large number of predictors to a smaller
number of predictors that are significantly related to dis-
ease. With forward selection, significant main effects and
interactions between these main effects are included in
the model. With backward selection, non-significant
effects are excluded from the full model containing all
parameters. There are drawbacks to the use of these stand-
ard selection procedures. With forward selection, interac-
tions can only be tested for the main effects included in
the model. Backward selection has the disadvantage that
it cannot properly work in the presence of too many vari-
ables relative to the number of cases. Even if it does work,
inclusion of too many parameters reduces the power of
the model. Applying the least absolute shrinkage and
selection operator (LASSO) [13] for selection of predictors
in logistic regression may be more useful than standard
selection procedures. This procedure shrinks the coeffi-
cients of predictors that are not important to zero, thereby
selecting a subset from a larger number of predictors. It
appears to have a better performance than standard back-
wards selection, but one disadvantage of the LASSO may
be that it does not reduce the number of predictors sub-
stantially [14]. Therefore, for selection of important pre-
dictors it will also be useful to apply other selection
methods before using logistic regression analysis to esti-
mate the strength of association between selected predic-
tors and disease.Page 4 of 15
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logistic regression as different model building strategies
may lead to different results [7]. Also, logistic regression
does not handle genetic heterogeneity well as it models
the relation between predictors and risk of disease for all
individuals in the sample [15] and therefore it does not
account for the presence of subgroups with different rela-
tionships between disease and genetic make-up. If differ-
ent subsets of genes work in different subsets of the
sample then logistic regression will probably not detect
the different genetic causes of disease [16]. To perform
logistic regression analysis many standard software pack-
ages (e.g. SAS, SPSS) are available.
Neural networks
Artificial neural networks are used to recognize patterns in
the observed data and can be applied to determine genetic
and environmental predictors related to disease. In
genetic epidemiology, neural networks can be used to
select SNPs that may contribute to disease.
In this section we will describe in the first part the struc-
ture of a network that is commonly used (the feed forward
network) and how neural networks usually are applied to
obtain the best structure. In the second part we describe
the parameter decreasing method [17], which can be used
to select a subset of important predictors among a larger
set of predictors. The genetic programming optimized
neural network (GPNN) [18] is a strategy that will be
described separately in the third part as it optimizes the
structure of the network in a different way and different
steps are involved to select the best model.
Structure of the feed forward network
A type of network commonly used consists of an input
layer, one or more hidden layers and an output layer. Each
layer is built up of nodes whereby one layer of nodes is
connected to the next layer and weights are assigned to the
connections. For example, with 10 input nodes, 6 hidden
layer nodes and 1 output node the number of connec-
tions, and thus weights, equals 10*6 + 6*1 = 66. This type
of network has a feed-forward structure: the flow of infor-
mation is from the input layer, via the nodes of the hidden
layer(s) to the node(s) of the output layer. The values of
the predictors are the input values for the neural network.
The combined input values are processed by each of the
nodes of the hidden layer by a transfer function. For
dichotomic outcome variables the transfer function is for
example the logistic function. A network containing one
hidden layer node with a logistic transfer function is
equivalent to logistic regression analysis [19] and net-
works containing more hidden nodes with logistic trans-
fer functions are generalizations of logistic regression to
more complex nonlinear relationships between predictors
and disease [20]. These non-linear relationships do not
need to be defined. More layers and nodes increase the
complexity of the model which enables the network to
model complex interactions between the predictor varia-
bles. Networks fall in between parametric and non-para-
metric approaches as they provide large but not unlimited
numbers of parameters to analysis methods [20].
The output of each node is determined by the outcome of
the transfer function and is processed by each node of the
next hidden layer (if present). The output of the last hid-
den layer is processed by the output node. The network
associates the input values of the predictors with the out-
put values given by the network. The amount of error
between the output values of the model and the observed
values is measured by an error function, for example a
sum squared error.
Training the network, i.e. essentially estimating all the
(hidden) parameters in the transfer function, is the proc-
ess of adjusting the weights of the connections whereby
weights are increased if they improve the output values
and decreased if they result in more error. The procedure
to optimize the weights is referred to as the back propaga-
tion algorithm [19]. The aim of the training is to obtain
the model containing weight values that minimize the
classification error of the network. Multi-fold cross-valida-
tion is used to divide the data into a training set and an
evaluation set. The network model is constructed using
the training set, the evaluation set is used to obtain the
prediction error of the model. The error between the pre-
dicted values and observed values of the evaluation set
gives the prediction error of the network. Each group cre-
ated by multi-fold cross-validation is used to obtain the
prediction error and the average prediction error is given
by the sum of the prediction errors divided by the number
of groups. The best model is the model with the lowest
classification and prediction error. After the model has
been obtained, predictors associated with the disease can
be selected.
Parameter decreasing method
To select important SNPs from the total group of SNPs
that were used to construct the network model, a parame-
ter decreasing method (PDM) can be used [17]. The pro-
cedure of PDM starts by deleting one SNP from the total
number of SNPs and constructs a model containing the
remaining SNPs. In turn each SNP is deleted from the
total number of SNPs and with the remaining SNPs a
model is constructed. From the constructed models the
model with the lowest number of misclassified subjects in
both the training and evaluation set is selected. This proc-
ess is repeated until one SNP remains. For each selected
model a measure of prediction accuracy is calculated by
the sum of true predicted cases and controls divided by
the total number of the evaluation sample. The predictionPage 5 of 15
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multi-fold cross-validation and the sum of the prediction
accuracies divided by the number of evaluation sets gives
the average prediction accuracy.
The PDM has been applied to select from 25 SNPs a subset
of susceptible SNPs of childhood allergic asthma [17]. The
average prediction accuracy started to decrease after SNPs
were excluded from the model containing 10 SNPs. To
minimize the effect of randomized initial weight values,
five PDM trials were performed and the importance of
SNPs that remained in the last 10 SNPs of each trial was
determined. For each trial the 10 SNPs were ordered from
1 to 10, based on the significance level of each SNP with
the disease. The sum over the five trials for the SNPs that
remained in the different trials was computed (sums can
range from 1 to 50) and it is assumed that SNPs with
higher scores are more important. The selected SNPs were
used to construct models in order of importance of SNPs
and for each model the prediction accuracy was calcu-
lated. Models with 10 of the most important SNPs or
more had high prediction accuracy. The model containing
the 10 most important SNPs had the same prediction
accuracy as the model containing all 25 SNPs.
A permutation test can be applied to determine whether at
least one of the selected SNPs is associated with the dis-
ease by randomly permuting the values of the selected
SNPs [21].
To investigate important interactions, Tomita et al. [17]
computed for 2-SNP and 3-SNP combinations the p-val-
ues by χ2-test and selected SNP combinations with a p-
value lower than 0.05. Combinations obtained in this
manner likely contain false positive results because correc-
tion for multiple testing has not been applied. Therefore
they used another measure of evaluation which they refer
to as the effective combination value (ECV). If SNPs in a
combination are independent, then the product of their
separate p-values is equal to the p-value of the combina-
tion. ECV is the ratio of a SNP combination p-value
divided by the product of SNP p-values and ECV < 1 sug-
gests that interaction is present. SNP combinations that
meet criteria for both χ2 p-values and ECV values are
selected.
Genetic programming optimized neural networks
A different strategy which can be used to select predictors
associated with disease is referred to as genetic program-
ming optimized neural networks [18]. Ritchie et al. [18]
developed this strategy to optimize the neural network
structure in order to improve selection of disease associ-
ated predictors. The back propagation algorithm
described in the first part of the neural network section
optimizes the weights. GPNN on the other hand not only
optimizes the weights, but also a set of inputs that is
selected from a larger set of predictors, the number of hid-
den layers and the number of nodes within the hidden
layer(s). Cross-validation is also applied in GPNN to
obtain for each partition of the data the best model and
the prediction error for this selected model.
The genetic programming procedure starts with random
selected models and evolves during the process to the
model with the best structure. The steps taken by GPNN
to obtain the best model are described here, more detailed
information can be found in [18,22]. First, a sample of all
possible different GPNN models is randomly generated,
using for each model a random subset of predictors from
the total number of predictors. These initial GPNN mod-
els may differ in size. For each of the generated models is
determined how well it fits the data, for example by its
classification error. From these models a new generation
of models is formed, which is equal to the number of
models that were generated at the start of the process. This
new generation of models is formed by directly copying a
predefined proportion of the best models (those with the
lowest classification error if classification error is used as
fitness function) as well as by exchanging different parts
between the models for another subset of best models.
Thus, compared to the previous generation the new gen-
eration consists of similar models (the best proportion of
models of the previous generation) and new models that
are the result of recombining models of the previous gen-
eration (which is another subset of best models than the
models that were copied). The size of the recombined
models is allowed to change. The new generation of mod-
els replaces the previous generation and the process is
repeated, bringing forth a next generation of models. This
process continues until GPNN reaches a certain criterion
(for example a classification error of zero or the maximum
number of generations specified by the researcher). The
model in the last generation that has the best fit (e.g. low-
est classification error) is denoted as the best GPNN
model and the prediction error for this model is deter-
mined by the remaining part of the data. For each parti-
tion created by cross-validation a best GPNN model with
the corresponding prediction error is obtained. For exam-
ple, 10-fold cross-validation will result in 10 best GPNN
models.
To determine the importance of predictors or predictor
combinations, a cross-validation consistency measure can
be used, which is the number of times a predictor or pre-
dictor combination is selected in a best model across all
validation sets, divided by the number of validation sets.
The predictor or predictor combination which has the
highest cross-validation consistency is denoted as the final
selected model.Page 6 of 15
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the study of Motsinger et al. [22] on Parkinson's disease.
Features of neural networks
The advantage of neural networks over logistic regression
is the possibility to flexibly model complex relationships
between the predictor variables and the disease status.
Tomita et al. [17] compared the prediction accuracy of
constructed models of neural networks with logistic
regression analysis for the models containing 25 and 10
SNPs. Constructed models by neural networks had high
prediction accuracy while the accuracy was low for logistic
regression analysis. A disadvantage of the PDM is that a
cut-off value for the prediction accuracy to select SNPs as
susceptible is not given.
In general, as the network can handle a limited number of
predictor variables depending on the number of observa-
tions in the dataset, faced with testing very large numbers
of genetic markers the network is subject to the dimen-
sionality problem [3]. GPNN however is not subject to the
dimensionality problem because it uses only a random
selection of predictors to build the initial GPNN models
and selects the most important predictors during the proc-
ess.
Studies investigating the power for neural networks using
PDM have not been found in the literature, thus informa-
tion about the power of the PDM to detect important
effects is not available at the present time. For GPNN, the
power to detect important SNPs in the presence of unre-
lated SNPs is higher compared to the commonly used feed
forward NN using a back propagation algorithm [18].
Using simulated data, Motsinger et al. [22] showed that
the power of GPNN to detect gene-gene interactions in
two and three locus interaction models is high. The
number of unrelated SNPs included however was not
large and further information on the power of GPNN to
detect genetic effects among a large set of unrelated SNPs
is needed.
If important interactions between SNPs are present, PDM
will likely be able to detect the SNPs involved in the inter-
action, because deleting a SNP would have an effect on
the prediction accuracy. Important interactions between
SNPs will therefore lead to selection of these SNPs. Also,
most of the 2-SNP and 3-SNP combinations identified by
Tomita et al. [17] were combinations of SNPs that had
been selected by the PDM procedure, followed by combi-
nations of selected and unselected SNPs and the least
number of combinations was found for unselected SNPs.
This suggests that neural networks are able to select SNP
combinations accurately [17].
For detection of the genetic polymorphisms involved in
disease, correlated markers are a problem for neural net-
works using the PDM. If one marker is associated with dis-
ease, but is correlated with another marker, deleting the
marker associated with disease will result in a smaller
decrease in the value of the prediction accuracy compared
to a situation of uncorrelated markers. Therefore, the
power to detect the association of the risk marker with the
disease will be reduced if this marker is correlated with
one or more other markers. The power of GPNN to detect
important predictors will not be reduced when correlation
between predictors is present. GPNN models containing
important predictors are more informative and will have
lower classification errors than models containing predic-
tors correlated with the important predictors. Important
predictors will therefore be selected during the process.
Neural networks can determine substructures within a
data set which enables them to handle genetic heterogene-
ity [20]. Software to perform neural network analysis of
case-control data using PDM is freely available [23], the
software is however not open-source. At the moment,
software for GPNN is not available.
Non parametric methods
Two step approaches
Several genetic association studies have employed the two
step approach, which consists of the following two steps:
- Step 1: determine a small number of potentially impor-
tant markers;
- Step 2: model interactions between important markers
and/or environmental predictors.
In the first step a non-parametric approach is applied to
reduce many markers to a small number of important
markers. For the second step environmental predictors
can be introduced to the model and logistic regression or
neural networks can be used to test gene-gene and/or
gene-environment interactions. In the two step approach
coupled-logistic regression can be applied to analyze
interactions between the selected markers obtained in the
first step [24,25]. The coupled-logistic regression proce-
dure first uses one forward selection step to model the
two-way and higher-order interactions between the
selected markers and environmental predictors if
included. Then backward selection is employed to elimi-
nate non-significant interactions.
Set association approach
A non-parametric approach for selecting a set of impor-
tant markers as a first step is the set association approach.
The set association approach is described in this section;
more detailed information can be found in [26]. InsteadPage 7 of 15
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association approach can also be used to analyze the effect
of quantitative predictor variables [27].
The set association approach starts by calculating a test-
statistic for each marker separately, which is a product of
two test statistics. The first statistic measures the associa-
tion of a marker with disease outcome. As measure of
association χ2 can be calculated from the contingency
table of alleles (or genotypes) with disease status, but
other statistics can be used as well. The deviation of a
marker from the null-hypothesis of Hardy-Weinberg
(HW) equilibrium is used as the second test-statistic,
which is chi-square distributed. χ2 values for deviations
from HW equilibrium are calculated in the case group and
larger deviations indicate an association between the
marker and the disease. Very large χ2 values for HW dise-
quilibrium in the control group can indicate genotyping
errors. To correct for the quality of genotyping, markers
showing large χ2 values in controls (e.g. χ2 values exceed-
ing the χ2 value corresponding to the 99-th percentile) are
deleted or set to zero [26]. Thus, for the calculation of the
test-statistic for each marker, information is used from
allelic association, deviation from HW equilibrium and
genotyping errors.
Subsequently, the markers are ordered based on their
value for the test-statistic. The set association approach
starts with the selection of the marker with the largest test
statistic and calculates sum statistics by adding each time
the most important marker from the group of unselected
markers. Increasing sums of markers are formed and the
number of markers in the sums ranges from 1 to a prede-
fined maximum number of M markers, for example 20.
The significance level of each sum of markers is tested
using a permutation test. The set association approach
uses, and holds fixed, the observed genotypes, but ran-
domly permutes the variable that indicates the disease sta-
tus. Many permuted samples are formed and for each
sample sum-statistics are calculated. The p-value for a cer-
tain sum of markers represents the proportion of per-
muted samples exceeding the value of the sum of markers
of the observed sample. Instead of testing many markers,
M sums (e.g. 20) are tested. Increased number of markers
in the sum with an association with disease will lower the
significance level of the sum. At a certain point the signif-
icance level will no longer decrease but increase as mark-
ers not contributing to disease are added to the sum.
Therefore, from the M sums tested the set of markers with
the lowest significance level is selected as the best set of
markers. This p-value is defined as test statistic and is eval-
uated by a second permutation test testing the null-
hypothesis of no association of the selected markers with
the disease-outcome. The second round of permutation
results in an overall p-value reducing the testing of M
sums to one sum. The multiple testing problem that arises
due to testing many markers has been overcome at this
stage of the set association approach.
Applications of the set association approach have been
reported for case-control studies on heart disease [27] and
Alzheimer's disease [28]
Features of the set association approach
The set association approach manages the dimensionality
problem by reducing the number of markers to a smaller
number of important markers. This method also provides
an overall significance level for the selected markers. In
general, the main advantage of two step approaches is that
large numbers of markers can be evaluated for their
importance in contributing to disease. Compared to the
Bonferonni and the False Discovery Rate procedures that
correct for multiple testing, the set association approach
has more power to identify genes involved in disease; sum
statistics are compounds of marker main effects which
have a better performance than approaches that test each
marker independently [29]. Furthermore, the power of
the set association approach is enhanced by using infor-
mation from allelic association, deviation from HW equi-
librium and genotyping errors.
The main disadvantage of the set association approach is
that genetic interactions are only tested for the markers
that are selected in the sum. Important interactions with
weak main effects will be missed.
To handle correlations between markers, Wille et al. [29]
proposed a method to adjust the test-statistic of a marker
for the correlation with the markers that are already
present in the sum. Using unadjusted test-statistics, mark-
ers could be included in the sum while these markers are
correlated with markers already contained in the sum. If
the correlation between markers concerns non-suscepti-
bility loci it will result in an overrepresentation of non-
susceptibility loci in the sums, reducing the power of the
approach. By using adjusted marker statistics the power of
the test is re-established.
Genetic heterogeneity will affect the performance of the
set association approach to identify important markers as
this approach tests the association of markers with disease
for the whole sample. Individuals affected due to different
loci decreases the association between each of the loci
with the disease and will result in a reduction of power of
the set association approach to detect these loci. The set
association approach is implemented in the program
Sumstat [26] which is freely available and open-source
[30]. At the moment, the adjustment of marker statistics
for their correlation with markers already included in the
sum has not been implemented in the software.Page 8 of 15
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Combinatorial methods search over all possible factor
combinations to find combinations with an effect on an
outcome variable. The combinatorial methods that will
be discussed are the combinatorial partitioning method
(CPM), the restricted partitioning method (RPM) and the
multifactor dimensionality reduction method (MDR).
Respectively, CPM and RPM have been described more
extensively by Nelson et al. [31] and Culverhouse et al.
[32]. Several recent reviews are available for MDR [33,34].
CPM and RPM aim to identify factor combinations that
explain best the variance of a quantitative phenotype.
MDR classifies factor combinations as having a low risk or
high risk on disease based on the presence of these com-
binations in cases versus controls. Both CPM and MDR
use multi-fold cross-validation to select the factor combi-
nations that have the best prediction of the outcome vari-
able and to compute the average proportion of variability
explained (CPM) or average prediction accuracy (MDR),
which is used to evaluate the validity of the obtained fac-
tor combinations. It is important to evaluate the validity
of the model to verify whether the combinations do not
present false positive results but are truly associated with
the disease [35].
Combinatorial partitioning method
CPM can be used to study the effect of factor combina-
tions on a quantitative phenotype. This phenotype can be
a variable underlying the disease of interest. An example
is to study factor combinations involved in the phenotype
blood pressure, which underlies cardiovascular disease.
To test whether a locus has an effect on a quantitative phe-
notype, analysis of variance (ANOVA) could be used. It
performs an overall test of the differences between the
mean phenotypic values of genotypes. However, with
many genotypes a posteriori testing the significance of the
differences between genotype means leads to the problem
of multiple testing. CPM has the advantage that it deter-
mines the loci combinations with an effect on a quantita-
tive phenotype and at the same time defines groups of
genotypes with similar phenotypic means [31]. In the
CPM a group of genotypes with similar phenotypic means
is referred to as a genotypic partition. Combinations of
two or more partitions make up a set of genotypic parti-
tions. CPM selects sets of genotypic partitions (consisting
of multi-locus genotypes) that predict variation of the
quantitative trait [31]. The CPM consists of three steps:
- Select loci combinations from all loci studied. For these
loci combinations, combine genotypes with similar phe-
notypes into partitions. Select from the total group of par-
titions each combination of genotypic partitions (thus
each set) that predicts a certain level of variance;
- Validate each selected set by multi-fold cross-validation;
- Select the most predictive sets and make inferences about
the combinations of loci and the genotype-phenotype
relationships.
In the first step the combinatorial partitioning method
selects all possible subsets of loci from the total group of
loci that is studied. For example, if 10 loci are studied and
all 2-loci combinations are considered, the number of
subsets of loci examined is equal to  = 45 pair wise
combinations. For each subset of loci all genotypic parti-
tions are examined. For two SNPs at autosomal loci the
number of genotype combinations equals nine and the
number of genotypic partitions investigated ranges from
two till nine. A set can for example consist of two geno-
typic partitions, one partition containing the multi-locus
genotypes AAbb, AaBb and aabb and the other partition
containing the remaining genotypes. CPM evaluates all
possible sets of genotype partitions and selects sets based
on two criteria. The first criterion is the proportion of phe-
notypic variability explained by a set. For each selected set
the variability between partitions should be much higher
than within the partitions because these sets will explain
the largest proportion of variance of the quantitative phe-
notype. The other criterion used is the number of individ-
uals in a set. Only a few individuals will be present for
genotypes with low frequency alleles and consequently
for partitions in which these genotypes are present. Small
numbers for genotypic partitions leads to unreliable esti-
mates of the partition means and partition variance.
When the number of individuals is set too low, spurious
effects may be found by chance. On the other hand, gen-
otypic partitions that do have an effect could be discarded
from further analyses when the number of individuals is
set too high [31].
In the second step each selected set is validated by the
multi-fold cross-validation method. For validation of the
selected sets all the groups generated by the cross-valida-
tion method, except for one, are used to estimate the
means of the genotypic partitions of a set. The remaining
group is used to compute the within partition sum of
squares, which is the predicted error for this group only.
The sum of the fractions of the different groups gives the
total predicted error of a set. If the multi-fold cross-valida-
tion is repeated several times, an average predicted error
can be calculated. From this averaged predicted error the
proportion of variability explained by a set is computed,
which is a measure of the predictive ability of the pheno-
type by a set of genotypic partitions. Sets with smaller pro-
portions of within sum of squares explain more variability
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dictive ability.
Based on the results of the cross-validation, the most pre-
dictive sets are selected in the third step. It is useful to
select more than one predictive set of genotypic partitions,
because by comparing the different sets more insight in
the relation between combinations of loci present in these
sets and the quantitative trait can likely be gained. To
obtain the statistical significance of the most predictive set
selected a permutation test can be performed. Phenotypic
outcomes are randomly assigned to the genotypes and for
each permutation sample the CPM is performed. The null-
hypothesis tested is that the most predictive set is not sig-
nificantly associated with the quantitative trait. The pro-
portion of sets exceeding the observed value of proportion
of variability explained by the most predictive set results
in a p-value for the most predictive set.
CPM has been applied in studies of plasma triglyceride
levels [31], plasma PAI-1 levels [36] and the relationship
between plasma t-PA and PAI-1 levels [37].
Restricted partitioning method
To overcome the computationally intensive search tech-
nique used by CPM, Culverhouse et al. [32] developed the
restricted partitioning method. Where CPM searches over
all possible combinations, RPM restricts its search in order
to avoid evaluation of genotype partitions that will not
explain much of the variation. The reasoning is that a
group consisting of genotypes for which the difference
between their mean values is large (thus having a large
within group variance), will not explain much of the total
variance of the quantitative trait and can therefore be dis-
carded for evaluation. The search procedure that is used
by RPM to select genotypic partitions consists of the fol-
lowing steps:
- Using a multiple comparison test, examine whether sig-
nificant differences between mean values of genotype
groups are present (at the start of the analysis each group
consists of one multi-locus genotype);
- from all the non-significant pairs of genotype groups,
combine the pair with the smallest difference between
their mean values into a new group, thereby reducing the
number of genotype groups to be evaluated with one;
- the procedure is reiterated until all differences between
pairs of genotype groups are significantly different.
If all the genotypes have significantly different means in
the first step the procedure ends at this step. Otherwise,
the number of genotype groups in the final partitioning is
less than the number of genotypes present at the start of
the analysis. To measure the importance of the final
model R2 is determined, which is the proportion of the
trait variation explained by the genotype groups. The sig-
nificance of the model is estimated by permutation test-
ing, generating a null distribution of R2. Bonferroni
correction is applied for the number of factor combina-
tions that have been tested. Factor combinations are
selected if the explained variance R2 by the combination is
found to be significant. Analysis with RPM has been per-
formed for irinotecan metabolism [32].
Multifactor dimensionality reduction method
The multifactor dimensionality reduction method ana-
lyzes genetic and/or environmental effects on a dichot-
omic outcome variable (e.g. disease status) rather than a
quantitative trait. MDR has been inspired by the CPM, but
the approach differs in many perspectives.
From the total group of factors studied, MDR evaluates all
possible N-factor combinations of genetic and/or discrete
environmental factors. Each cell of the N-factor combina-
tion is assigned to either a low risk or high risk group. A
certain threshold, defined as the ratio of cases to controls,
determines the risk group to which a factor combination
is assigned. For example, for all nine possible genotype
combinations of each two loci combination the risk status
is determined. If the threshold is set to one and the cell for
a genotype combination contains more cases than con-
trols, that genotype combination is determined as high
risk. Thus, MDR assigns each combination (e.g. multi-
locus genotype) within a N-factor combination to a high
risk or low risk group, thereby constructing a new factor
consisting of the two risk groups. The process of construct-
ing a new factor as a function of two or more other factors
is referred to as constructive induction and MDR can
therefore be viewed as a constructive induction approach
[38]. MDR evaluates the ability of this new factor to clas-
sify and predict disease status by multi-fold cross-valida-
tion.
Multi-fold cross-validation divides the observed data in
equal subsets. One subset remains aside, the other subsets
are used to build the model. The N-factor model with the
lowest classification error is selected and for this model
the remaining subset is used to obtain the prediction accu-
racy. By turns each subset is used to obtain the prediction
accuracy for the best classifying model that has been build
by the other subsets. The model with the highest predic-
tion accuracy is selected as the best N-factor model.
Different numbers N of factors are evaluated. For each
number of factors, multi-fold cross-validation is used to
select the best classifying N-factor combination by meas-
uring the prediction accuracy of the model. Cross-valida-
tion consistency (also discussed in the geneticPage 10 of 15
(page number not for citation purposes)
BMC Genetics 2006, 7:23 http://www.biomedcentral.com/1471-2156/7/23programming optimized neural networks section) is
another measure for selecting the best classifying N-factor
combination: it is the number of times a N-factor combi-
nation is selected as the best model across all validation
sets, divided by the number of validation sets. The N-fac-
tor model with the highest prediction accuracy and/or the
highest cross-validity consistency is selected. If one best
model is found with the highest prediction accuracy and
another model with the highest cross-validation consist-
ency, the most parsimonious model is chosen for describ-
ing the observed data. For example, if the best 2-factor
combination model has the highest prediction accuracy
and the best 3-factor combination model has the highest
cross-validation consistency, the 2-factor combination
model is selected. A permutation test is performed to
obtain the statistical significance of the most predictive N-
factor model. For each permuted dataset the best model is
selected and the prediction accuracy or cross-validity con-
sistency is determined. The p-value is obtained using the
distribution of the prediction accuracy or cross-validity
consistency under the null-hypothesis.
The MDR approach has been applied for example to case-
control data of prostate cancer [39], type 2 diabetes [40],
myocardial infarction [35], hypertension [41] and spo-
radic breast cancer [42].
Features of the combinatorial methods
The combinatorial methods discussed above select from
all factor combinations those factor combinations that
best explain the outcome variable thereby solving the
dimensionality problem. Because both CPM and MDR are
computationally intensive procedures the number of fac-
tors to be analyzed by these methods is moderate. Selec-
tion methods to preselect factors can be used as a first step
[38] and such filter methods are part of the MDR software
[43]. These methods can be applied before using MDR,
enabling the user of the MDR software to analyze large
numbers of factors. Although RPM has the advantage that
it relieves the computational intensity of CPM and
thereby has the potential to analyze many interacting loci,
the multiple testing problem is still a challenge for this
method.
One of the merits of the combinatorial methods is their
high power to identify high-order interactions between
loci while main effects are not present [32,44]. The power
of the MDR approach to detect gene-gene interactions in
the absence of main effects was examined by Ritchie et al.
[44]. Using simulated datasets, they studied 6 different
models of interaction between two loci, including in the
datasets noise due to 5 percent genotyping error, 5 percent
missing data, 50 percent phenocopy and 50 percent
genetic heterogeneity. Without noise factors, the power of
the MDR method to detect the two-locus interaction for
the 6 models was in between 80 and 100 percent. The
drop in power due to genotyping errors, missing data or
the combination of these noise factors was very small.
Phenocopies had a large effect on the power for 4 models
and genetic heterogeneity had the largest impact on the
power for 5 of the 6 models. The power is reduced by phe-
nocopies or genetic heterogeneity, because different com-
binations of factors causing the disease will decrease the
prediction accuracy and cross validity consistency of a
model [35]. The power to detect the interaction for each
of the models was decreased to around 1 percent for the
combination of phenocopies and genetic heterogeneity. If
phenocopies are present, the power of the MDR approach
can be increased if environmental factors causing the dis-
ease are included in the analysis. Environmental differ-
ences in the population can be assessed to define
subgroups after which MDR can be applied to each group,
or the environmental factors can be included in the MDR
analysis. To account for genetic heterogeneity, cluster
analysis of genetic markers can be employed (see back-
ground section). MDR analysis for the different clusters
can be performed or the cluster status can be included as
a covariate [44]. If the presence of genetic heterogeneity is
not known beforehand the power for CPM, RPM and
MDR is largely reduced.
As CPM, RPM and MDR select the model that has the best
prediction of disease status, the model that contains the
most information will be selected. Risk predictors contain
more information than predictors correlated with the risk
predictors and the power of these methods to detect risk
SNPs will not be reduced when correlation between pre-
dictors is present. Software for CPM is not available, but a
program for this method can easily be made by a compe-
tent statistical geneticist. Software implementing RPM is
available from Culverhouse et al. [32]. Also, open-source
software for RPM is currently under development [43].
MDR software, originally discussed by Hahn et al. [45], is
freely available and is open-source [43]. A MDR Permuta-
tion Testing module to perform permutation testing is
also freely available [43].
Recursive partitioning methods
Recursive partitioning methods partition the total dataset
recursively into smaller and more homogeneous subsets
to fit models for predicting the value of a continuous or
categorical outcome from many predictor variables. These
models are called tree-based models as the splits of the
data into more and more homogeneous subsets can be
pictured by a tree graph [15]. Regression and classification
trees are respectively applied to continuous and categori-
cal outcome variables. Here, the application of random
forests of classification trees to case-control data is dis-
cussed.Page 11 of 15
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first internal node called the root node that contains the
total sample. The root node is split into two nodes to
improve the homogeneity of the case group and control
group compared to the root node. This split is based on a
cut-off point of the predictor variable that partitions the
total sample best into the two groups of cases and con-
trols, for example a split based on a certain SNP with one
subset containing wild-type homozygous and hetero-
zygous individuals (genotypes AA and Aa) and the other
subset containing homozygous mutant individuals (gen-
otype aa). Each of these two nodes is split again, whereby
splits are based on the predictor variable that improves
the homogeneity of the resulting subsets (this predictor
may differ for each node). A node that is not further split
into two nodes is called a terminal node. A recursive par-
titioning method that can be used for selection of impor-
tant predictors contributing to disease is the random
forests approach.
The random forests approach
In the random forests approach a group of tree-based
models is used to select predictors with an important con-
tribution to an outcome variable [16,46]. For each model,
every split is based on a random selected subset of all pre-
dictors studied. More important predictors will discrimi-
nate best between cases and controls and will therefore be
closer to the root node and present in most of the trees.
On the other hand, less important predictors will be less
present in the different trees and closer to the terminal
nodes [46]. The random forests approach has been
described in more detail by Lunetta et al. [16] and Bureau
et al. [46].
The prediction accuracy of the forest
For each tree in the forest, the total sample started with at
the root node is generated by bootstrap sampling. With
bootstrap sampling individuals are sampled from the
observed population sample. The number of individuals
in the bootstrap sample equals the number of individuals
in the observed sample and because sampling is per-
formed with replacement, some individuals can be
present more than once in the bootstrap sample while
other individuals are left out. The bootstrap sample is
used to build the tree and the left-out individuals to
obtain the prediction of the forest. The predictor values of
a left-out individual determine which terminal node, or
class, this individual is assigned to for a certain tree. The
class to which most of the individuals of the bootstrap
sample are assigned to is the predicted class of the tree for
the left-out individual. The prediction for the forest is
obtained by counting the predictions over the trees for
which the individual was left out the bootstrap sample.
The class with the most predictions is the prediction of the
forest. In case-control data the prediction accuracy of the
forest is given by the difference between the proportion of
correct and incorrect classification of the left-out individ-
uals. The prediction accuracy of the forest is used to obtain
a measurement of importance of each predictor.
The importance of predictors
Predictors that best classify the population into cases and
controls are assumed to be important predictors of dis-
ease-status. The importance of a predictor is given by an
importance index IM which denotes the importance of a
predictor taken other predictors into account. The values
of the predictor for which the index is computed need to
be randomized for the left-out individuals to remove any
association between the predictor and disease status. The
importance index for predictor A is then the difference in
prediction accuracy of disease status by the predictor vec-
tor and the same predictor vector with predictor A ran-
domly permuted for the left-out individuals. Larger
differences in prediction accuracy between the two predic-
tor vectors indicate more important predictors. The ran-
dom forests approach orders the predictors according to
their importance. Computing the importance index can
be extended to pairs of predictors whereby the predictor
values of both predictors are permuted. Application of
random forests to case-control data has been reported for
asthma [46].
Features of the random forests approach
As the random forests approach selects the most impor-
tant predictors among all predictors, the dimensionality
problem is circumvented, but the approach does not pro-
vide a cut-off value of the importance index to determine
which predictors should be retained for further analysis
[16]. The advantage of the random forests approach is that
it is able to test many predictors. Permuting the predictor
values for the left-out individuals does not only remove
the association between the permuted predictor and the
outcome variable, but also the interaction effects of the
permuted predictor with other predictors, if present.
Thereby, the interactions of the predictor with other pre-
dictors are captured in the importance index. Lunetta et al.
[16] tested the performance of the random forests
approach compared to Fisher's Exact test in ranking risk
SNPs using simulated data. Genetic heterogeneity was
included in the disease models. If interaction between two
risk markers is present, the random forests approach has a
better performance to rank these risk markers than univar-
iate ranking methods because the importance of each
marker involved in the interaction will increase. More
interactions and larger groups that interact increase the
relative performance [16]. Therefore, markers with weak
main effect but significant interaction with other markers
can be detected by the random forests approach. The joint
importance of subsets of predictors can be tested for all
markers if the size of the subset is small, but testing thePage 12 of 15
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interactions becomes computationally unfeasible. As
Province et al. [15] point out, recursive partitioning meth-
ods are able to detect genetic heterogeneity. This assertion
is confirmed by the study of Lunetta et al. [16]. Genetic
heterogeneity is handled because different models are fit-
ted to subsets of the data defined by early splits in the trees
[15,16]. Limited simulations suggest that correlated pre-
dictors are a problem for the random forests approach as
it leads to a decrease of the predictor importance for each
correlated risk SNP [16]. Software for the random forests
is freely available and is open-source [47].
Conclusion
An overview of the strengths and weaknesses of the meth-
ods discussed is given in table 1.
The dimensionality problem is not solved by the method
of logistic regression. Applying a parameter decreasing
method within neural networks to select important pre-
dictors is a useful approach if moderate numbers of SNPs
are tested. However, neural networks can not handle the
dimensionality problem either if the number of predictors
tested becomes too large. Logistic regression and neural
networks are therefore less useful to approach association
studies with large numbers of predictor variables. These
methods can be applied to model the effects of a group of
selected predictors, including interaction terms and other
potential risk factors. For example in the two step
approach coupled logistic regression can be used after the
markers have been selected in the first step. Genetic pro-
gramming optimized neural network is able to select and
model important predictors from a set of predictors, but
the performance of GPNN to detect important SNPs in the
presence of large numbers of unrelated SNPs needs to be
investigated.
Both the set association approach and random forests
approach can handle a large number of predictors and are
useful in reducing the large amount of predictors to those
predictors with an important contribution to disease.
Another argument for employment of the random forests
approach is the possibility to detect the presence of
genetic heterogeneity. The combinatorial methods are
useful to give more insight in interaction patterns for sets
of genetic and/or environmental predictor variables. CPM
and RPM can be applied in the study of quantitative phe-
notypes underlying the disease of interest, MDR is useful
for analyzing effects on disease status.
As each of the non-parametric methods has its strengths
and weaknesses, genetic association studies should be
approached by several methods. For genetic association
studies using the case-control design to analyze complex
diseases, the application of the set association approach in
combination with the MDR and the random forests
Table 1: Comparison of the different methods.
Logistic 
regression
Neural networks Set 
association
CPM RPM MDR Random 
forests
PDM GPNN
Outcome variable dichotomous categorical 
continuous
categorical 
continuous
dichotomous continuous continuous dichotomous categorical
Dimensionality no no yes yes yes yes yes yes
Number of 
predictors
few moderate many many moderate many* moderate† many
Power to detect 
important effects
low no info high high high high high high
Detection of 
interactions
no yes yes no yes yes yes yes‡
Correlated 
predictors
no no yes n.i.** yes yes yes no
Genetic 
heterogeneity
no yes yes no no no no yes
Software available
Open source
yes yes
no
no yes
yes
no at request 
and under 
development
yes
yes
yes
yes
For the problems of dimensionality, correlated predictors and genetic heterogeneity yes and no indicate respectively that a method is able or not 
able to handle the problem. For detection of interactions when main effects are absent yes and no indicate respectively that a method is able or not 
able to detect interactions while main effects of the loci involved in the interaction are small or absent.
* RPM is subject to the multiple testing problem.
† MDR can analyze a moderate number of factors, but filter methods that are part of the MDR software can be applied before using MDR, enabling 
the user of the MDR software to analyze large numbers of factors.
‡ Interactions contribute to the importance of predictors.
** n.i.: not implemented, adjustment of the test statistics for correlation between markers is not implemented in the software.Page 13 of 15
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important genes and interaction patterns involved, as
each of these methods approach the analysis of multiple
SNP data differently. Similarities and differences in the
results generated by these methods will provide valuable
information whether selected SNPs are likely to contrib-
ute to disease by their main effects or whether gene-gene
interactions play a role. Thus the combination of these
methods will give more insight in the etiology of complex
diseases. These methods can also be used in a multistep
approach, discussed by Moore et al. [38], to detect and
interpret interactions. In the first step of this approach a
subset of important SNPs is selected from the total
number of SNPs. The set association approach and/or ran-
dom forests could be applied as method for selection of
important predictors. The next step is to apply a construc-
tive induction approach to construct from this subset of
SNPs a new factor consisting of high risk and low risk gen-
otype combinations. MDR can be used at this second step
as a constructive induction approach. The ability of this
constructed factor to classify and predict disease status is
evaluated in the third step, for example by multi-fold
cross-validation which is also implemented in the MDR
approach. Besides detecting statistical interactions this
multistep approach provides the means to statistically
interpret the detected interactions in the fourth step. At
this last step visual tools can be used for model interpre-
tion. This multistep approach is flexible as at each step
many different methods can be used [38].
More statistical methods to analyze multiple SNPs in rela-
tion to complex diseases are becoming available. What the
features of other newly developed methods for analysis of
multiple SNPs will be has to be studied and compared to
the methods discussed in this commentary. Also, applica-
tions of the methods in genetic association studies will
have to be performed in order to examine their practical
value for the field of genetic epidemiology.
In this commentary the strengths and weaknesses of
methods to approach the statistical challenge to detect
gene-gene interactions associated with the disease or dis-
ease related outcome of interest have been discussed.
However, these methods test interactions statistically,
which is only a first step in the unravelling of the interact-
ing underlying biological mechanisms. The biological
interpretation of statistically detected gene-gene interac-
tions is not straightforward and forms another challenge
for genetic epidemiologists. Statistical interaction is
detected on the population level by relating genotype
information to interindividual differences in phenotype
while biological interaction is the result of physical inter-
action of biomolecules which takes place at the individual
level [2]. To address this challenge, Moore et al. propose
the application of systems biology (a synthesis of multiple
disciplines) to unicellular organisms, reasoning that
understanding of the relationship between statistical and
biological interaction in these organisms will reveal some
basic underlying principles and thereby will help to
understand how statistical interaction is related to human
complex diseases [2].
In conclusion, statistical methods have been developed
that enable genetic epidemiologists to detect important
genetic and/or environmental predictors associated with
disease or disease related variables. These methods have
different strengths and weaknesses. Applying a combina-
tion of these methods will provide insight in the main
effects and interaction patterns involved in the etiology of
complex diseases.
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